AMG 786
Alternative Names: AMG-786Latest Information Update: 27 Jun 2024
At a glance
- Originator Amgen
- Class Obesity therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 27 Jun 2024 Discontinued - Phase-I for Obesity (In volunteers) in USA (PO) (Amgen Pipeline, June 2024)
- 02 May 2024 Amgen completes a phase I trial in Obesity (In volunteers) in USA (PO) (NCT05406115)
- 26 Jul 2022 Phase-I clinical trials in Obesity (In volunteers) in USA (PO) (NCT05406115) (Amgen pipeline, August 2022)